JP2019526532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526532A5 JP2019526532A5 JP2018567866A JP2018567866A JP2019526532A5 JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5 JP 2018567866 A JP2018567866 A JP 2018567866A JP 2018567866 A JP2018567866 A JP 2018567866A JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- amount ranging
- amount
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 73
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 24
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 18
- 239000002904 solvent Substances 0.000 claims 17
- 239000001797 sucrose acetate isobutyrate Substances 0.000 claims 14
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims 14
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 claims 14
- 229930003427 Vitamin E Natural products 0.000 claims 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 12
- 235000019165 vitamin E Nutrition 0.000 claims 12
- 229940046009 vitamin E Drugs 0.000 claims 12
- 239000011709 vitamin E Substances 0.000 claims 12
- 239000008186 active pharmaceutical agent Substances 0.000 claims 9
- 229960002903 benzyl benzoate Drugs 0.000 claims 9
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 9
- 229960002930 sirolimus Drugs 0.000 claims 9
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 239000002202 Polyethylene glycol Substances 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- XSIFPSYPOVKYCO-UHFFFAOYSA-N butyl benzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 claims 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical group COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- UDEWPOVQBGFNGE-UHFFFAOYSA-N propyl benzoate Chemical compound CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 claims 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 2
- DUAYDERMVQWIJD-UHFFFAOYSA-N 2-n,2-n,6-trimethyl-1,3,5-triazine-2,4-diamine Chemical compound CN(C)C1=NC(C)=NC(N)=N1 DUAYDERMVQWIJD-UHFFFAOYSA-N 0.000 claims 1
- MLLAPOCBLWUFAP-UHFFFAOYSA-N 3-Methylbutyl benzoate Chemical compound CC(C)CCOC(=O)C1=CC=CC=C1 MLLAPOCBLWUFAP-UHFFFAOYSA-N 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- FEXQDZTYJVXMOS-UHFFFAOYSA-N Isopropyl benzoate Chemical compound CC(C)OC(=O)C1=CC=CC=C1 FEXQDZTYJVXMOS-UHFFFAOYSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 239000003732 agents acting on the eye Substances 0.000 claims 1
- KYZHGEFMXZOSJN-UHFFFAOYSA-N benzoic acid isobutyl ester Natural products CC(C)COC(=O)C1=CC=CC=C1 KYZHGEFMXZOSJN-UHFFFAOYSA-N 0.000 claims 1
- LSLWNAOQPPLHSW-UHFFFAOYSA-N butan-2-yl benzoate Chemical compound CCC(C)OC(=O)C1=CC=CC=C1 LSLWNAOQPPLHSW-UHFFFAOYSA-N 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- 229940023490 ophthalmic product Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- LYDRKKWPKKEMNZ-UHFFFAOYSA-N tert-butyl benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1 LYDRKKWPKKEMNZ-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022056589A JP2022088568A (ja) | 2016-06-30 | 2022-03-30 | デポー製剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356613P | 2016-06-30 | 2016-06-30 | |
| US62/356,613 | 2016-06-30 | ||
| US201662440658P | 2016-12-30 | 2016-12-30 | |
| US62/440,658 | 2016-12-30 | ||
| PCT/US2017/039968 WO2018005777A1 (en) | 2016-06-30 | 2017-06-29 | Depot formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022056589A Division JP2022088568A (ja) | 2016-06-30 | 2022-03-30 | デポー製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526532A JP2019526532A (ja) | 2019-09-19 |
| JP2019526532A5 true JP2019526532A5 (enExample) | 2020-08-06 |
| JP7051721B2 JP7051721B2 (ja) | 2022-04-11 |
Family
ID=60786467
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567866A Active JP7051721B2 (ja) | 2016-06-30 | 2017-06-29 | デポー製剤 |
| JP2022056589A Pending JP2022088568A (ja) | 2016-06-30 | 2022-03-30 | デポー製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022056589A Pending JP2022088568A (ja) | 2016-06-30 | 2022-03-30 | デポー製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10668011B2 (enExample) |
| EP (1) | EP3478285A4 (enExample) |
| JP (2) | JP7051721B2 (enExample) |
| KR (1) | KR20190025635A (enExample) |
| CN (2) | CN115645399A (enExample) |
| AU (2) | AU2017290143A1 (enExample) |
| BR (1) | BR112018077259A2 (enExample) |
| CA (1) | CA2972296A1 (enExample) |
| IL (1) | IL263714A (enExample) |
| MX (1) | MX387477B (enExample) |
| PH (1) | PH12018502615A1 (enExample) |
| SG (1) | SG11201810618QA (enExample) |
| TW (1) | TWI765898B (enExample) |
| UA (1) | UA124768C2 (enExample) |
| WO (2) | WO2018005777A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2979971A1 (en) * | 2015-03-18 | 2016-09-22 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
| EP3478285A4 (en) | 2016-06-30 | 2020-07-22 | Durect Corporation | DEPOSIT FORMULATIONS |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| CA3097927A1 (en) | 2018-05-01 | 2019-11-07 | Chibi, Inc. | Liquid depot for non-invasive sustained delivery of agents to the eye |
| MX2020011535A (es) * | 2018-05-01 | 2020-11-24 | Chibi Inc | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |
| CA3141337A1 (en) | 2019-05-24 | 2020-12-03 | Piedmont Animal Health Inc. | Long-acting injectable formulations and use thereof |
| CN113117049A (zh) * | 2019-12-31 | 2021-07-16 | 齐鲁制药有限公司 | 一种索玛鲁肽原位凝胶制剂及其制备方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443340A (en) | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
| US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| KR970007322B1 (ko) | 1991-12-19 | 1997-05-07 | 미쓰이도오아쓰 가가쿠 가부시키가이샤 | 폴리히드록시 카르복실산 및 그 제조방법 |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| DK1006935T3 (da) * | 1995-06-07 | 2005-06-06 | Durect Corp | Styret afgivelsessystem med en væske med höj viskositet |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| JP4724354B2 (ja) | 2001-02-23 | 2011-07-13 | ジェネンテック， インコーポレイテッド | 注射用の崩壊性ポリマー |
| US8501215B2 (en) | 2002-07-31 | 2013-08-06 | Guohua Chen | Injectable multimodal polymer depot compositions and uses thereof |
| JP2006511475A (ja) | 2002-09-18 | 2006-04-06 | トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 脈絡膜新生血管症の抑制方法 |
| BR0315304A (pt) | 2002-11-06 | 2005-08-16 | Alza Corp | Formulações com depósito para liberação controlada |
| SI1575569T1 (sl) | 2002-12-13 | 2010-12-31 | Durect Corp | Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale |
| CA2518791A1 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell-schedule dependent anticancer agents |
| WO2005027906A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| SI2767292T1 (sl) | 2004-09-17 | 2017-01-31 | Durect Corporation | Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2006039336A2 (en) | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| GB2438544A (en) | 2005-02-09 | 2007-11-28 | Cooper Internat Corp | Liquid formulations for treatment of diseases or conditions |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| CA2602525A1 (en) * | 2005-03-21 | 2006-09-28 | Macusight, Inc. | Drug delivery systems for treatment of diseases or conditions |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| CN101443004B (zh) | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| CN1973822A (zh) | 2006-12-20 | 2007-06-06 | 山东蓝金生物工程有限公司 | 一种含雷帕霉素的抗癌组合物 |
| ES2447516T3 (es) | 2006-12-21 | 2014-03-12 | Stryker Corporation | Formulaciones de liberación sostenida que comprenden cristales BMP-7 |
| JP5599705B2 (ja) | 2007-05-18 | 2014-10-01 | デュレクト コーポレーション | 改良されたデポー製剤 |
| WO2009023877A2 (en) * | 2007-08-16 | 2009-02-19 | Macusight, Inc. | Formulations for treatment of ocular diseases or conditions |
| EP2067471B1 (en) | 2007-12-06 | 2018-02-14 | Durect Corporation | Oral pharmaceutical dosage forms |
| WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
| US20120114637A1 (en) | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
| MX347014B (es) * | 2010-11-24 | 2017-04-07 | Durect Corp | Composición para administración de fármaco biodegradable. |
| EP2782590A4 (en) | 2011-11-23 | 2016-08-03 | Durect Corp | BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS |
| JP6282231B2 (ja) | 2012-01-23 | 2018-02-21 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子 |
| CN109602692B (zh) * | 2013-03-11 | 2022-11-04 | 度瑞公司 | 包含高粘度液体载体的可注射控制释放组合物 |
| CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| AU2014233462A1 (en) | 2013-03-15 | 2015-10-01 | Durect Corporation | Compositions with thixotropy and enhanced dissolution reproducibility and stability |
| JP6530744B2 (ja) | 2013-05-24 | 2019-06-12 | アイコン バイオサイエンス インコーポレイテッド | 白内障手術後の炎症における徐放性デキサメタゾンの使用 |
| CN107249570B (zh) | 2014-11-21 | 2022-08-09 | 丹麦技术大学 | 用于局部药物释放的凝胶制剂 |
| CA2979971A1 (en) | 2015-03-18 | 2016-09-22 | Santen Pharmaceutical Co., Ltd. | Sustained-release pharmaceutical composition |
| JP6872322B2 (ja) | 2015-07-01 | 2021-05-19 | 参天製薬株式会社 | クエン酸エステルを含有するデポ剤 |
| EP3478285A4 (en) | 2016-06-30 | 2020-07-22 | Durect Corporation | DEPOSIT FORMULATIONS |
| ES2944576T3 (es) | 2017-01-06 | 2023-06-22 | Santen Pharmaceutical Co Ltd | Administración intratumoral de sirólimus para el tratamiento del cáncer de próstata |
-
2017
- 2017-06-29 EP EP17821242.9A patent/EP3478285A4/en not_active Withdrawn
- 2017-06-29 SG SG11201810618QA patent/SG11201810618QA/en unknown
- 2017-06-29 CA CA2972296A patent/CA2972296A1/en active Pending
- 2017-06-29 BR BR112018077259A patent/BR112018077259A2/pt active Search and Examination
- 2017-06-29 CN CN202211265979.6A patent/CN115645399A/zh active Pending
- 2017-06-29 JP JP2018567866A patent/JP7051721B2/ja active Active
- 2017-06-29 KR KR1020197002239A patent/KR20190025635A/ko not_active Ceased
- 2017-06-29 AU AU2017290143A patent/AU2017290143A1/en not_active Abandoned
- 2017-06-29 US US15/637,401 patent/US10668011B2/en not_active Expired - Fee Related
- 2017-06-29 CN CN201780037977.2A patent/CN109310680B/zh not_active Expired - Fee Related
- 2017-06-29 WO PCT/US2017/039968 patent/WO2018005777A1/en not_active Ceased
- 2017-06-29 TW TW106121825A patent/TWI765898B/zh not_active IP Right Cessation
- 2017-06-29 MX MX2018016424A patent/MX387477B/es unknown
- 2017-06-29 UA UAA201900958A patent/UA124768C2/uk unknown
-
2018
- 2018-12-11 PH PH12018502615A patent/PH12018502615A1/en unknown
- 2018-12-14 IL IL263714A patent/IL263714A/en unknown
- 2018-12-27 WO PCT/US2018/067724 patent/WO2019133735A1/en not_active Ceased
-
2020
- 2020-04-27 US US16/859,443 patent/US20200352852A1/en not_active Abandoned
-
2022
- 2022-03-30 JP JP2022056589A patent/JP2022088568A/ja active Pending
-
2023
- 2023-05-05 AU AU2023202823A patent/AU2023202823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526532A5 (enExample) | ||
| AU764626B2 (en) | Pharmaceutical formulations of taxanes | |
| WO2020083971A3 (en) | New anthelmintic compounds | |
| JP2017527532A5 (enExample) | ||
| MX2013012579A (es) | Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilicos y metodos para prepararlos y usarlos. | |
| AR110270A1 (es) | Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos | |
| RU2014129268A (ru) | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля | |
| JP2018507252A5 (enExample) | ||
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| FI3586825T3 (fi) | Biohajoavat lääkeaineen annostelukoostumukset | |
| WO2009111057A4 (en) | Fulvestrant formulations | |
| KR20180024010A (ko) | 동결건조된 약제학적 조성물 | |
| WO2014118808A3 (en) | Ticagrelor solid dispersion | |
| WO2018201167A3 (en) | Propionic acid derivatives and methods of use thereof | |
| JP2020531462A5 (enExample) | ||
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| JP2017525758A5 (enExample) | ||
| RU2016140272A (ru) | Стабильные ветеринарные антигельминтные композиции | |
| IL278548B2 (en) | Pharmaceutical preparations containing dronabinol and sprays containing the same pharmaceutical preparations | |
| FI3258920T3 (fi) | Juomavesilääkkeenä käytettäväksi soveltuva kiinteä farmaseuttinen annosmuoto | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| WO2020135647A1 (en) | Pharmaceutical composition and preparation method thereof | |
| JP2011512362A5 (enExample) | ||
| HRP20211558T1 (hr) | Formulacija |